prikaz prve stranice dokumenta Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
  Download
PDF 654.15 KB
Scientific paper - Original scientific paper
Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
Neurology and Therapy, 12 (2022), 1; 25-37. https://doi.org/10.1007/s40120-022-00422-z
Habek, Mario; Drulović, Jelena; Brecl Jakob, Gregor; Barbov, Ivan; Radulovic, Ljiljana; Rajda, Cecilia; Rejdak, Konrad; Turčáni, Peter

Cite this document

Habek, M., Drulović, J., Brecl Jakob, G., Barbov, I., Radulovic, Lj., Rajda, C. ... Turčáni, P. (2022). Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy, 12. (1), 25-37. doi: 10.1007/s40120-022-00422-z

Habek, Mario, et al. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy, vol. 12, no. 1, 2022, pp. 25-37. https://doi.org/10.1007/s40120-022-00422-z

Habek, Mario, Jelena Drulović, Gregor Brecl Jakob, Ivan Barbov, Ljiljana Radulovic, Cecilia Rajda, Konrad Rejdak and Peter Turčáni. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy 12, no. 1 (2022): 25-37. https://doi.org/10.1007/s40120-022-00422-z

Habek, M., et al. (2022) 'Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers', Neurology and Therapy, 12(1), pp. 25-37. doi: 10.1007/s40120-022-00422-z

Habek M, Drulović J, Brecl Jakob G, Barbov I, Radulovic Lj, Rajda C, and sur.. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy [Internet]. 2022 November 17 [cited 2024 October 08];12(1):25-37. doi: 10.1007/s40120-022-00422-z

M. Habek, et al., "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers", Neurology and Therapy, vol. 12, no. 1, pp. 25-37, November 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:261927. [Accessed: 08 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
AuthorMario Habek
AuthorJelena Drulović
AuthorGregor Brecl Jakob
AuthorIvan Barbov
AuthorLjiljana Radulovic
AuthorCecilia Rajda
AuthorKonrad Rejdak
AuthorPeter Turčáni
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Based on the results of the pivotal CLARITY study, cladribine tablets were approved for use in the European Union in 2017 as a high-efficacy therapy for highly active relapsing-remitting multiple sclerosis (MS). Cladribine tablets are used as an induction therapy: half of the total dose is given in year 1 and the other half in year 2. In the CLARITY Extension trials, repeating the dose routinely in years 3 and 4, was not associated with significantly improved disease control. However, there is very limited evidence on how to manage people with MS (pwMS) beyond year 4, which is increasingly important because more and more patients are now ≥ 4 years after cladribine treatment. Overall, postapproval data show that treatment with two cladribine cycles effectively controls disease activity in the long term. However, there is general agreement that some pwMS with suboptimal response could benefit from retreatment. This study reviews the practical aspects of using cladribine tablets, summarizes the evidence from clinical trials and real-world studies on the safety and efficacy of cladribine, and proposes a treatment algorithm developed by expert consensus for pwMS previously treated with cladribine. In brief, we propose that additional courses of cladribine tablets should be considered in patients with minimal (no relapses, 1-2 new lesions) or moderate (1 relapse, 3-4 new lesions) disease activity, while significant disease activity (> 1 relapse, > 3 new lesions) or progression should warrant a switch to another high-efficacy treatment (HET). More evidence is needed to improve the treatment guidelines for pwMS who previously received cladribine.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleNeurology and Therapy
Numberingvol. 12, no. 1, pp. 25-37
p-ISSN2193-8253
e-ISSN2193-6536
DOIhttps://doi.org/10.1007/s40120-022-00422-z
URN:NBNurn:nbn:hr:105:261927
Publication2022-11-17
Document URLhttps://link.springer.com/10.1007/s40120-022-00422-z
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2023-07-11 11:55:26